Patent · US Active

Methods of treating ovarian cancer by modulating SnoN

US8211646B1 · kind B1 · utility

0Cited by

0References

12Claims

0Family size

Assignee

University of South Florida · US

Inventors

Meera Nanjundan · Tampa, US
Gordon B. Mills · Houston, US
Dawn Smith · Carp, CA

Key dates

Filing date	Nov 16, 2009
Grant date	Jul 3, 2012
Priority date	—
Expiry date	Nov 16, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/178
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Genomic analysis of ovarian cancers demonstrated a regional chromosomal increase in expression and gene duplication. TGF-β stimulation indicated a link between SnoN RNA and TGF-β. In TIOSE, SnoN protein levels were reduced 15 min post TGF-β-stimulation, likely by proteosome-mediated degradation. SnoN inhibition decreased cell growth between 20 and 50% concurrent with increased p21 levels. Stable expression of SnoN led to growth arrest through induction of senescence. Collectively, these results implicate SnoN levels in multiple roles during ovarian carcinogenesis: promoting cellular proliferation in ovarian cancer cells and as a positive mediator of cell cycle arrest and senescence in non-transformed ovarian epithelial cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.